Renaissance Technologies LLC Purchases 65,365 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Renaissance Technologies LLC boosted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 12.7% in the first quarter, Holdings Channel reports. The fund owned 578,265 shares of the company’s stock after acquiring an additional 65,365 shares during the period. Renaissance Technologies LLC’s holdings in 4D Molecular Therapeutics were worth $5,384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics in the third quarter worth about $41,000. Daiwa Securities Group Inc. boosted its stake in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares during the period. Susquehanna Portfolio Strategies LLC bought a new position in 4D Molecular Therapeutics in the 4th quarter worth approximately $77,000. Martingale Asset Management L P lifted its holdings in shares of 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after buying an additional 1,303 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $90,000. 99.27% of the stock is currently owned by institutional investors.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Kirn sold 12,415 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at $8,760,956.85. This trade represents a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 197,226 shares of company stock worth $2,200,677. Corporate insiders own 7.90% of the company’s stock.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $10.28 on Thursday. The firm has a market cap of $537.44 million, a P/E ratio of -4.00 and a beta of 2.73. The firm’s 50-day simple moving average is $10.67 and its 200-day simple moving average is $9.71. 4D Molecular Therapeutics, Inc. has a twelve month low of $5.33 and a twelve month high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. B. Riley Financial began coverage on shares of 4D Molecular Therapeutics in a research note on Friday, July 31st. They issued a “buy” rating and a $37.00 price objective on the stock. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group set a $33.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.67.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.